Lucid Diagnostics annual shareholders’ equity
2020
2021
2022
2023
2024
2025
Lucid Diagnostics Shareholders’ Equity Growth & History (LUCD)
Lucid Diagnostics's shareholders’ equity was $10.9M for fiscal 2025.
View full Lucid Diagnostics company overviewLucid Diagnostics annual shareholders’ equity history
| Fiscal year | Period ended | Shareholders’ equity | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $10.9M | $5.5M | +102.86% |
| 2024 | 2024-12-31 | $5.4M | $7.7M | — |
| 2023 | 2023-12-31 | −$2.3M | −$25.4M | — |
| 2022 | 2022-12-31 | $23.0M | −$31.7M | −57.90% |
| 2021 | 2021-12-31 | $54.7M | $68.3M | — |
| 2020 | 2020-12-31 | −$13.5M | — | — |
Lucid Diagnostics quarterly shareholders’ equity
Q4.20
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Shareholders’ equity | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $10.9M | $3.1M | +38.98% |
| Q1 2026 | 2026-03-31 | $4.0M | $9.4M | — |
| Q4 2025 | 2025-12-31 | $10.9M | $5.5M | +102.86% |
| Q3 2025 | 2025-09-30 | $25.8M | $19.5M | +307.62% |
| Q2 2025 | 2025-06-30 | $7.9M | −$8.1M | −50.80% |
| Q1 2025 | 2025-03-31 | −$5.4M | −$17.3M | — |
| Q4 2024 | 2024-12-31 | $5.4M | $7.7M | — |
| Q3 2024 | 2024-09-30 | $6.3M | $3.8M | +147.97% |
| Q2 2024 | 2024-06-30 | $16.0M | $908,000 | +6.02% |
| Q1 2024 | 2024-03-31 | $11.9M | −$13.0M | −52.24% |
| Q4 2023 | 2023-12-31 | −$2.3M | −$25.4M | — |
| Q3 2023 | 2023-09-30 | $2.6M | −$25.0M | −90.72% |
| Q2 2023 | 2023-06-30 | $15.1M | −$21.2M | −58.41% |
| Q1 2023 | 2023-03-31 | $24.9M | −$21.6M | −46.43% |
| Q4 2022 | 2022-12-31 | $23.0M | −$31.7M | −57.90% |
| Q3 2022 | 2022-09-30 | $27.5M | $51.7M | — |
| Q2 2022 | 2022-06-30 | $36.2M | — | — |
| Q1 2022 | 2022-03-31 | $46.5M | — | — |
| Q4 2021 | 2021-12-31 | $54.7M | $68.3M | — |
| Q3 2021 | 2021-09-30 | −$24.1M | — | — |
| Q4 2020 | 2020-12-31 | −$13.5M | — | — |
Lucid Diagnostics shareholders’ equity trends
Over the last five fiscal years, Lucid Diagnostics's shareholders’ equity increased from −$13.5M to $10.9M, a change of $24.5M. The latest reported quarter, Q2 2026, shows $10.9M.
About the metric
What shareholders’ equity means
Shareholders’ equity is the residual accounting value attributable to shareholders after liabilities are subtracted from assets. It can change through earnings, losses, dividends, share issuance, repurchases, and other comprehensive income.
Calculation and source
SEC-reported shareholders’ equity
TickerStat standardizes stockholders’ or shareholders’ equity reported in company SEC filings at each balance-sheet date. Negative equity is retained because it can be economically meaningful. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Lucid Diagnostics source filings ↗Community posts
Lucid Diagnostics receives Medicare payments and closes $15 million financing
Lucid Diagnostics ($LUCD) said it has begun receiving Medicare reimbursement for its EsoGuard esophageal cancer test at the established rate of $1,938.01 per test. The announcement advances the reimbursement story from submission of claims ...
